Intravesical and systemic chemotherapy of murine bladder cancer

M. S. Soloway

Research output: Contribution to journalArticle

137 Citations (Scopus)

Abstract

Transitional cell carcinomas induced in syngeneic mice by the carcinogen N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT) resemble their human counterpart both grossly and histologically and have been used in an animal model to evaluate antitumor drugs for activity in bladder cancer. In C3H/He mice, the first tumors are seen after 8 months on FANFT and an incidence of 70 to 100% is observed by 11 months. In the first of two long term studies, single or combination chemotherapy was initiated after 10 months of FANFT. The drugs were administered for 3 weeks. Each treatment regimen was capable of producing a significant reduction in the mean bladder weight when compared to a group not receiving therapy (108 mg) cyclophosphamide (CY) (42.9); dactinomycin (49.6); cis-diaminedichloroplatinum(II) (56.4); and Adriamycin (69.5). The combination of CY with Adriamycin (37.3) of 5-fluorouracil (38.3) was superior to CY alone. In the second long-term study using this autochthonous tumor model, identical therapeutic regimens were initiated earlier in the carcinogenic process, after 5 or 7 months on FANFT. The regimens were: CY, 75 mg/kg; adriamycin, 3 mg/kg, 2 times/week; CY + 5 fluorouracil, 45 mg/kg CY + adriamycin, 5 mg/kg; and Bacillus Calmette-Guerin 1 x 107 organisms. CY effected a significant reduction in the mean bladder weight, 30.8 mg at 5 months and 42.1 mg at 7 months (control, 44.6; p<0.001 and <0.05). The combination of CY with 5-fluorouracil and adriamycin was superior to CY alone. Mice receiving Bacillus Calmette-Guerin for either 3.5 or 5.5 months had a significant increase in the size of resulting tumors as indicated by the mean bladder weight. Intravesical chemotherapy was also evaluated by determining which drugs were capable of inhibiting the implantation of transitional tumor cells. A single cell suspension of a transplantable FANFT-induced tumor is capable of implanting on the denuded murine urothelium. Since tumor cell implantation might be a factor in the high recurrence rate of human bladder cancer, irrigation with an effective cytotoxic agent might reduce this incidence. Intravesical Epodyl and epipodophyllotoxin significantly reduced the incidence of tumor cell implantation in the animal model. Thiotepa exhibited moderate antitumor activity. It is hoped that information gained from these animal models, which allow evaluation of many drugs within a relatively short period of time, will identify drugs effective in transitional call carcinoma and lead to therapeutic trials in patients with bladder cancer.

Original languageEnglish
Pages (from-to)2918-2929
Number of pages12
JournalCancer Research
Volume37
Issue number8 II
StatePublished - Dec 1 1977
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
FANFT
Cyclophosphamide
Drug Therapy
Doxorubicin
Neoplasms
Fluorouracil
Urinary Bladder
Animal Models
Mycobacterium bovis
Weights and Measures
Ethoglucid
Incidence
Pharmaceutical Preparations
Podophyllotoxin
Thiotepa
Urothelium
Drug Evaluation
Inbred C3H Mouse
Transitional Cell Carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Intravesical and systemic chemotherapy of murine bladder cancer. / Soloway, M. S.

In: Cancer Research, Vol. 37, No. 8 II, 01.12.1977, p. 2918-2929.

Research output: Contribution to journalArticle

Soloway, MS 1977, 'Intravesical and systemic chemotherapy of murine bladder cancer', Cancer Research, vol. 37, no. 8 II, pp. 2918-2929.
Soloway, M. S. / Intravesical and systemic chemotherapy of murine bladder cancer. In: Cancer Research. 1977 ; Vol. 37, No. 8 II. pp. 2918-2929.
@article{bb5992b646d44450bb695936400b1c45,
title = "Intravesical and systemic chemotherapy of murine bladder cancer",
abstract = "Transitional cell carcinomas induced in syngeneic mice by the carcinogen N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT) resemble their human counterpart both grossly and histologically and have been used in an animal model to evaluate antitumor drugs for activity in bladder cancer. In C3H/He mice, the first tumors are seen after 8 months on FANFT and an incidence of 70 to 100{\%} is observed by 11 months. In the first of two long term studies, single or combination chemotherapy was initiated after 10 months of FANFT. The drugs were administered for 3 weeks. Each treatment regimen was capable of producing a significant reduction in the mean bladder weight when compared to a group not receiving therapy (108 mg) cyclophosphamide (CY) (42.9); dactinomycin (49.6); cis-diaminedichloroplatinum(II) (56.4); and Adriamycin (69.5). The combination of CY with Adriamycin (37.3) of 5-fluorouracil (38.3) was superior to CY alone. In the second long-term study using this autochthonous tumor model, identical therapeutic regimens were initiated earlier in the carcinogenic process, after 5 or 7 months on FANFT. The regimens were: CY, 75 mg/kg; adriamycin, 3 mg/kg, 2 times/week; CY + 5 fluorouracil, 45 mg/kg CY + adriamycin, 5 mg/kg; and Bacillus Calmette-Guerin 1 x 107 organisms. CY effected a significant reduction in the mean bladder weight, 30.8 mg at 5 months and 42.1 mg at 7 months (control, 44.6; p<0.001 and <0.05). The combination of CY with 5-fluorouracil and adriamycin was superior to CY alone. Mice receiving Bacillus Calmette-Guerin for either 3.5 or 5.5 months had a significant increase in the size of resulting tumors as indicated by the mean bladder weight. Intravesical chemotherapy was also evaluated by determining which drugs were capable of inhibiting the implantation of transitional tumor cells. A single cell suspension of a transplantable FANFT-induced tumor is capable of implanting on the denuded murine urothelium. Since tumor cell implantation might be a factor in the high recurrence rate of human bladder cancer, irrigation with an effective cytotoxic agent might reduce this incidence. Intravesical Epodyl and epipodophyllotoxin significantly reduced the incidence of tumor cell implantation in the animal model. Thiotepa exhibited moderate antitumor activity. It is hoped that information gained from these animal models, which allow evaluation of many drugs within a relatively short period of time, will identify drugs effective in transitional call carcinoma and lead to therapeutic trials in patients with bladder cancer.",
author = "Soloway, {M. S.}",
year = "1977",
month = "12",
day = "1",
language = "English",
volume = "37",
pages = "2918--2929",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "8 II",

}

TY - JOUR

T1 - Intravesical and systemic chemotherapy of murine bladder cancer

AU - Soloway, M. S.

PY - 1977/12/1

Y1 - 1977/12/1

N2 - Transitional cell carcinomas induced in syngeneic mice by the carcinogen N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT) resemble their human counterpart both grossly and histologically and have been used in an animal model to evaluate antitumor drugs for activity in bladder cancer. In C3H/He mice, the first tumors are seen after 8 months on FANFT and an incidence of 70 to 100% is observed by 11 months. In the first of two long term studies, single or combination chemotherapy was initiated after 10 months of FANFT. The drugs were administered for 3 weeks. Each treatment regimen was capable of producing a significant reduction in the mean bladder weight when compared to a group not receiving therapy (108 mg) cyclophosphamide (CY) (42.9); dactinomycin (49.6); cis-diaminedichloroplatinum(II) (56.4); and Adriamycin (69.5). The combination of CY with Adriamycin (37.3) of 5-fluorouracil (38.3) was superior to CY alone. In the second long-term study using this autochthonous tumor model, identical therapeutic regimens were initiated earlier in the carcinogenic process, after 5 or 7 months on FANFT. The regimens were: CY, 75 mg/kg; adriamycin, 3 mg/kg, 2 times/week; CY + 5 fluorouracil, 45 mg/kg CY + adriamycin, 5 mg/kg; and Bacillus Calmette-Guerin 1 x 107 organisms. CY effected a significant reduction in the mean bladder weight, 30.8 mg at 5 months and 42.1 mg at 7 months (control, 44.6; p<0.001 and <0.05). The combination of CY with 5-fluorouracil and adriamycin was superior to CY alone. Mice receiving Bacillus Calmette-Guerin for either 3.5 or 5.5 months had a significant increase in the size of resulting tumors as indicated by the mean bladder weight. Intravesical chemotherapy was also evaluated by determining which drugs were capable of inhibiting the implantation of transitional tumor cells. A single cell suspension of a transplantable FANFT-induced tumor is capable of implanting on the denuded murine urothelium. Since tumor cell implantation might be a factor in the high recurrence rate of human bladder cancer, irrigation with an effective cytotoxic agent might reduce this incidence. Intravesical Epodyl and epipodophyllotoxin significantly reduced the incidence of tumor cell implantation in the animal model. Thiotepa exhibited moderate antitumor activity. It is hoped that information gained from these animal models, which allow evaluation of many drugs within a relatively short period of time, will identify drugs effective in transitional call carcinoma and lead to therapeutic trials in patients with bladder cancer.

AB - Transitional cell carcinomas induced in syngeneic mice by the carcinogen N-[4-(5-nitro-2-furyl)-2-thiazolyl]formamide (FANFT) resemble their human counterpart both grossly and histologically and have been used in an animal model to evaluate antitumor drugs for activity in bladder cancer. In C3H/He mice, the first tumors are seen after 8 months on FANFT and an incidence of 70 to 100% is observed by 11 months. In the first of two long term studies, single or combination chemotherapy was initiated after 10 months of FANFT. The drugs were administered for 3 weeks. Each treatment regimen was capable of producing a significant reduction in the mean bladder weight when compared to a group not receiving therapy (108 mg) cyclophosphamide (CY) (42.9); dactinomycin (49.6); cis-diaminedichloroplatinum(II) (56.4); and Adriamycin (69.5). The combination of CY with Adriamycin (37.3) of 5-fluorouracil (38.3) was superior to CY alone. In the second long-term study using this autochthonous tumor model, identical therapeutic regimens were initiated earlier in the carcinogenic process, after 5 or 7 months on FANFT. The regimens were: CY, 75 mg/kg; adriamycin, 3 mg/kg, 2 times/week; CY + 5 fluorouracil, 45 mg/kg CY + adriamycin, 5 mg/kg; and Bacillus Calmette-Guerin 1 x 107 organisms. CY effected a significant reduction in the mean bladder weight, 30.8 mg at 5 months and 42.1 mg at 7 months (control, 44.6; p<0.001 and <0.05). The combination of CY with 5-fluorouracil and adriamycin was superior to CY alone. Mice receiving Bacillus Calmette-Guerin for either 3.5 or 5.5 months had a significant increase in the size of resulting tumors as indicated by the mean bladder weight. Intravesical chemotherapy was also evaluated by determining which drugs were capable of inhibiting the implantation of transitional tumor cells. A single cell suspension of a transplantable FANFT-induced tumor is capable of implanting on the denuded murine urothelium. Since tumor cell implantation might be a factor in the high recurrence rate of human bladder cancer, irrigation with an effective cytotoxic agent might reduce this incidence. Intravesical Epodyl and epipodophyllotoxin significantly reduced the incidence of tumor cell implantation in the animal model. Thiotepa exhibited moderate antitumor activity. It is hoped that information gained from these animal models, which allow evaluation of many drugs within a relatively short period of time, will identify drugs effective in transitional call carcinoma and lead to therapeutic trials in patients with bladder cancer.

UR - http://www.scopus.com/inward/record.url?scp=0017744507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017744507&partnerID=8YFLogxK

M3 - Article

VL - 37

SP - 2918

EP - 2929

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 8 II

ER -